Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3645-3649

  Miyake, Hideaki ^a   Muramaki, Mototsugu ^b   Kurahashi, Toshifumi ^b   Yamanaka, Kazuki ^a   Hara, Isao ^b  

^a HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Prostate cancer; Urine; VEGF

Indexed keywords

VASCULOTROPIN;

ARTICLE; CANCER HORMONE THERAPY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME IMMUNOASSAY; EVALUATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN URINE LEVEL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23344433788     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Risaw W: Mechanism of angiogenesis. Nature 386: 671-674, 1997.
2. Hanahan D and Folkman J: Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
3. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
4. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-424, 1998.
5. George DJ, Halabi S, Shepard TF Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW and Cancer and Leukemia Group B 9480: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7: 1932-1936, 2001.
6. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM and Slawin KM: Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 22: 1655-1663, 2004.
7. Zeng Y, Opeskin K, Baldwin ME, Horvath LG, Achen MG, Stacker SA, Sutherland RL and Williams ED: Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 10: 5137-5144, 2004.
8. Bigler SA, Deering RE and Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24: 220-226, 1993.
9. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI and Agus DB: Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8: 3226-3231, 2002.
10. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ and Tilley WD: A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 62: 854-859, 2002.
11. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A and Freeman MR: Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 159: 651-659, 2001.
12. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA and Dinney CP: Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8: 2714-2724, 2002.
13. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S and Muramatsu T: A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64: 3365-3370, 2004.
14. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA and Small EJ: Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A Cancer and Leukemia Group B Study. Cancer Res 61: 2533-2536, 2001.
15. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Menard C and Camphausen K: Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 22: 499-506, 2004.
16. Haggstrom S, Stattin P, Wikstrom P, Bergh A and Damber JE: Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer. BJU Int 88: 110-116, 2001.
17. Kohli M, Kaushal V, Spencer HJ and Mehta P: Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urology 61: 765-769, 2003.
18. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW and Bubley GJ: Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 63: 327-332, 2004.
19. Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA and Eble JN: Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res 24: 2135-2140, 2004.
20. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S and Kamidono S: Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology 53: 302-307, 1999.
21. International Union Against Cancer: TNM Classification of Malignant Tumors (Sobin LH and Wittekind CH, eds.). New York, John Wiley & Sons, pp. 170-173, 1997.
22. Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G and Loening S: Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 45: 216-224, 2000.
23. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ and Pettaway CA: Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ confined from pathologically advanced prostate cancers. Clin Cancer Res 6: 2295-2308, 2000.
24. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI and Walsh PC: The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological staging in men with localized prostate cancer. J Urol 150: 110-114, 1993.